CY1106328T1 - Συνθεση glyburide - Google Patents

Συνθεση glyburide

Info

Publication number
CY1106328T1
CY1106328T1 CY20061101349T CY061101349T CY1106328T1 CY 1106328 T1 CY1106328 T1 CY 1106328T1 CY 20061101349 T CY20061101349 T CY 20061101349T CY 061101349 T CY061101349 T CY 061101349T CY 1106328 T1 CY1106328 T1 CY 1106328T1
Authority
CY
Cyprus
Prior art keywords
glyburide
natural form
composition
glyburide composition
methoxybenzamide
Prior art date
Application number
CY20061101349T
Other languages
English (en)
Inventor
Gillian Cave
Sarah J. Nicholson
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of CY1106328T1 publication Critical patent/CY1106328T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/59—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε μία φυσική μορφή της γνωστής φαρμακευτικής ουσίας GLYBURIDE, επίσης γνωστής ως glibenclamide και χημικώς ορισθείσας ως 5-χλωρο-Ν-[2-[4-[[[(κυκλοεξυλαμινο)-καρβονυλ]αμινο]σουλφονυλ]φαινυλ]αιθυλ]-2-μεθοξυβενζαμίδιο (Merck Index, 10η έκδοση, σελ. 642), καθώς και σε μορφές δοσολογίας, π.χ. δισκία και κάψουλες, ενσωματώνοντας την αναφερθείσα φυσική μορφή από glyburide.
CY20061101349T 2000-01-14 2006-09-20 Συνθεση glyburide CY1106328T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48370300A 2000-01-14 2000-01-14
PCT/US2001/000234 WO2001051463A1 (en) 2000-01-14 2001-01-04 Glyburide composition

Publications (1)

Publication Number Publication Date
CY1106328T1 true CY1106328T1 (el) 2011-10-12

Family

ID=23921174

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101349T CY1106328T1 (el) 2000-01-14 2006-09-20 Συνθεση glyburide

Country Status (37)

Country Link
US (2) US20010036479A1 (el)
EP (1) EP1250321B1 (el)
JP (1) JP4787446B2 (el)
KR (1) KR100739906B1 (el)
CN (1) CN1210258C (el)
AR (1) AR031547A1 (el)
AT (1) ATE330937T1 (el)
AU (1) AU771705B2 (el)
BG (1) BG65782B1 (el)
BR (1) BR0107564A (el)
CA (1) CA2397294C (el)
CY (1) CY1106328T1 (el)
CZ (1) CZ20022429A3 (el)
DE (1) DE60120916T2 (el)
DK (1) DK1250321T3 (el)
EE (1) EE05020B1 (el)
ES (1) ES2264967T3 (el)
GE (1) GEP20043299B (el)
HU (1) HU228825B1 (el)
IL (2) IL150383A0 (el)
LT (1) LT5024B (el)
LV (1) LV12914B (el)
MX (1) MXPA02006835A (el)
MY (1) MY128577A (el)
NO (1) NO328152B1 (el)
NZ (1) NZ519920A (el)
PT (1) PT1250321E (el)
RO (1) RO121381B1 (el)
RU (1) RU2244707C2 (el)
SK (1) SK286925B6 (el)
TN (1) TNSN01005A1 (el)
TR (1) TR200201798T2 (el)
TW (1) TWI287989B (el)
UA (1) UA73968C2 (el)
UY (1) UY26529A1 (el)
WO (1) WO2001051463A1 (el)
ZA (1) ZA200205528B (el)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767249B2 (en) * 2001-06-07 2010-08-03 Hewlett-Packard Development Company, L.P. Preparation of nanoparticles
US20050271737A1 (en) * 2001-06-07 2005-12-08 Chinea Vanessa I Application of a bioactive agent to a substrate
EP1465628A2 (en) * 2002-03-21 2004-10-13 Teva Pharmaceutical Industries Ltd. Fine particle size pioglitazone
KR100897890B1 (ko) 2002-06-17 2009-05-18 인벤티아 헬스케어 피브이티. 엘티디. 티아졸리딘디온 및 바이구아나이드를 함유하는 다층 정제및 그의 제조 방법
SI1677792T1 (sl) 2003-10-31 2016-02-29 Takeda Pharmaceutical Company Limited Trden pripravek, ki obsega pioglitazon, glimepirid in polioksietilen sorbitan maščobnokislinski ester
CN100455279C (zh) * 2004-04-29 2009-01-28 美时化学制药股份有限公司 口服延迟释放锭剂组成物及其制法
CA2563325C (en) * 2004-04-29 2010-06-22 Lotus Pharmaceutical Co., Ltd. Oral modified-release lozenges and their preparation method
CN100341495C (zh) * 2004-12-29 2007-10-10 三九医药股份有限公司 格列本脲固体分散体、口服组合物及其制备方法
WO2006109175A2 (en) * 2005-04-11 2006-10-19 Aurobindo Pharma Limited Solid dosage form of an antidiabetic drug
US8529537B2 (en) * 2005-08-05 2013-09-10 Kimberly-Clark Worldwide, Inc. Absorbent article with enclosures
NZ565955A (en) 2005-08-22 2011-08-26 Melior Pharmaceuticals I Inc Methods and formulations for modulating lyn kinase activity and treating related disorders
CN101287467B (zh) * 2005-08-22 2011-01-19 梅里奥尔医药I公司 用于调节Lyn激酶活性和治疗相关病症的方法和制剂
US20090252790A1 (en) * 2006-05-13 2009-10-08 Novo Nordisk A/S Tablet formulation
WO2008026668A1 (fr) * 2006-08-31 2008-03-06 Daiichi Sankyo Company, Limited Composition médicale contenant un agent d'amélioration de la résistance à l'insuline
EP1967182A1 (en) * 2007-03-07 2008-09-10 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a salt of rosigliatazone
US8552184B2 (en) 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
WO2010048287A2 (en) 2008-10-22 2010-04-29 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Radioprotective agents
EP2520298A1 (en) 2011-05-03 2012-11-07 Assistance Publique, Hopitaux De Paris Pharmaceutical composition comprising sulfonylureas (glibenclamide) or meglitinides for use for treating hyperglycaemia or for promoting growth of a premature infant
CN102743354A (zh) * 2012-07-31 2012-10-24 南京正科制药有限公司 瑞格列奈片及其制备方法
CN103142521B (zh) * 2013-03-21 2014-06-25 西南药业股份有限公司 格列本脲片及其制备方法
CN104127423A (zh) * 2014-07-30 2014-11-05 沈阳药科大学 格列喹酮衍生物及其制备方法和应用
CN104127424A (zh) * 2014-07-30 2014-11-05 沈阳药科大学 格列本脲衍生物及其制备方法和应用
WO2018191166A1 (en) 2017-04-10 2018-10-18 Melior Pharmaceuticals I, Inc. Treatment of adipocytes
CN113143940A (zh) * 2020-12-30 2021-07-23 成都恒瑞制药有限公司 一种抗糖尿病药物组合物的制备方法
WO2023012610A1 (en) * 2021-08-03 2023-02-09 Avaca Pharma Private Limited Formulations, compositions and methods for the treatment of stroke

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
DE1185180B (de) 1963-10-19 1965-01-14 Hoechst Ag Verfahren zur Herstellung von Benzolsulfonylharnstoffen
US3454635A (en) 1965-07-27 1969-07-08 Hoechst Ag Benzenesulfonyl-ureas and process for their manufacture
CA889876A (en) 1970-09-10 1972-01-04 Frank W. Horner Limited Purification of glyburide
US4060634A (en) * 1973-09-26 1977-11-29 Boehringer Mannheim G.M.B.H. Rapidly resorbable glibenclamide
DE2348334C2 (de) * 1973-09-26 1982-11-11 Boehringer Mannheim Gmbh, 6800 Mannheim Neue Zubereitungsform des N-4-[2-(5-Chlor-2-methoxybenzamido)äthyl]- phenyl-sulfonyl-N'-cyclohexylharnstoffs
US4916163A (en) * 1985-06-04 1990-04-10 The Upjohn Company Spray-dried lactose formulation of micronized glyburide
DE3833439A1 (de) 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
RU2026670C1 (ru) 1988-10-05 1995-01-20 Дзе Апджон Компани Способ получения тонкодисперсного твердого фармацевтического вещества
US5258185A (en) 1989-08-23 1993-11-02 Bauer Kurt H Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use
DE59206324D1 (de) * 1991-12-05 1996-06-20 Alfatec Pharma Gmbh Pharmazeutisch applizierbares nanosol und verfahren zu seiner herstellung
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
DE4323636A1 (de) * 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) * 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
DE19721467A1 (de) * 1997-05-22 1998-11-26 Basf Ag Verfahren zur Herstellung kleinteiliger Zubereitungen biologisch aktiver Stoffe
JP2002504137A (ja) 1997-06-18 2002-02-05 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー チアゾリジンジオンおよびメトホルミンを用いる糖尿病の治療
GB9715306D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
DE69811233T2 (de) * 1997-10-27 2003-11-20 Merck Patent Gmbh Feste lösungen und dispersionen von eines schlecht wasserlöslichen wirkstoffes
PT974356E (pt) 1998-07-15 2004-02-27 Merck Sante Sas Comprimidos compreendendo uma combinacao de metformina e de glibenclamida
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents

Also Published As

Publication number Publication date
WO2001051463A1 (en) 2001-07-19
JP2003519681A (ja) 2003-06-24
IL150383A0 (en) 2002-12-01
US6830760B2 (en) 2004-12-14
UA73968C2 (en) 2005-10-17
BG65782B1 (bg) 2009-11-30
US20010036479A1 (en) 2001-11-01
NO328152B1 (no) 2009-12-21
CN1395560A (zh) 2003-02-05
TWI287989B (en) 2007-10-11
SK286925B6 (sk) 2009-07-06
DE60120916T2 (de) 2007-02-15
KR100739906B1 (ko) 2007-07-16
RO121381B1 (ro) 2007-04-30
MXPA02006835A (es) 2003-01-28
US20030185880A1 (en) 2003-10-02
EE05020B1 (et) 2008-06-16
LV12914B (en) 2003-01-20
HUP0203852A2 (hu) 2003-04-28
HU228825B1 (en) 2013-05-28
NO20023367D0 (no) 2002-07-12
CN1210258C (zh) 2005-07-13
KR20020073169A (ko) 2002-09-19
HUP0203852A3 (en) 2005-05-30
PL356210A1 (en) 2004-06-14
SK9832002A3 (en) 2003-07-01
BG106870A (en) 2003-03-31
UY26529A1 (es) 2001-08-27
CZ20022429A3 (cs) 2003-06-18
AU771705B2 (en) 2004-04-01
RU2002121626A (ru) 2004-01-10
BR0107564A (pt) 2002-10-01
MY128577A (en) 2007-02-28
GEP20043299B (en) 2004-03-10
CA2397294C (en) 2011-03-22
LT5024B (lt) 2003-06-25
EP1250321B1 (en) 2006-06-21
NO20023367L (no) 2002-09-04
ATE330937T1 (de) 2006-07-15
ES2264967T3 (es) 2007-02-01
DK1250321T3 (da) 2006-07-31
TR200201798T2 (tr) 2002-11-21
NZ519920A (en) 2004-06-25
EE200200393A (et) 2003-10-15
RU2244707C2 (ru) 2005-01-20
AR031547A1 (es) 2003-09-24
DE60120916D1 (de) 2006-08-03
ZA200205528B (en) 2003-10-10
IL150383A (en) 2007-03-08
AU2474001A (en) 2001-07-24
EP1250321A1 (en) 2002-10-23
CA2397294A1 (en) 2001-07-19
LT2002085A (en) 2003-01-27
PT1250321E (pt) 2006-09-29
JP4787446B2 (ja) 2011-10-05
TNSN01005A1 (en) 2005-11-10

Similar Documents

Publication Publication Date Title
CY1106328T1 (el) Συνθεση glyburide
TR200002953T2 (tr) İki halkalı hidroksamik asit türevleri
EA200200571A1 (ru) Новая композиция и ее применение
BR0214469A (pt) 17alfa-alquil-17beta-óxi-estratrienos e produtos intermediários para sua preparação, aplicação dos 17alfa-alquil-17beta-óxi-estratrienos para a preparação de medicamentos bem como preparações farmacêuticas
AR033423A1 (es) Sales farmaceuticas constituidas de una sustancia activa farmaceutica y al menos un edulcorante, medicamentos que contienen estas sales y uso de estas sales para la preparacion de medicamentos
TR199903191T2 (xx) Vorikonazol i�eren ila� form�lasyonlar�.
AR029733A1 (es) Composicion principalmente cosmetica o farmaceutica que se presenta en forma solida
EA200600598A1 (ru) Лекарственные формы замедленного высвобождения
BR0316605A (pt) Derivados de fluorglicosìdeos aromáticos, medicamentos contendo estes compostos e sua aplicação
BR0317283A (pt) Derivados heterocìclicos de flúor-glicosìdeo, medicamentos contendo estes compostos e seu uso
ATE433317T1 (de) Medizinische aerosolformulierung von antidiabetika
HUP0001310A2 (hu) N-[2'-{[(4,5-Dimetil-3-izoxazolil)-amino]-szulfonil}-4-(2-oxazolil)-(1,1'-bifenil-2-il)-metil]-N-metil-3,3-dimetil-butiramid és N-(4,5-dimetil-3-izoxazolil)-2'-[(3,3-dimetil-2-oxo-1-pirrolidinil)-metil]-4'-(2-oxazolil)-(1,1'-bifenil-2-il)...
EA200400664A1 (ru) Фармацевтические композиции, включающие метформин и глибенкламид, применяемые для лечения сахарного диабета типа ii
BR0108893A (pt) Composição farmacêutica, composto e processo de preparação de compostos
BRPI0212894B8 (pt) composto ou sal do mesmo farmaceuticamente aceitável e composição farmacêutica
AR033688A1 (es) Composicion parenteral reconstituible
TR200401793T4 (tr) Perindopril tuzu ve bunu içeren farmasötik bileşimler.
UY24308A1 (es) Tabletas exentas de aglutinante que contienen tramadol o una sal de tramadol, para administracion oral
DE60042831D1 (de) Pharmazeutisch aktive sulfonylaminosäurederivate
CO4940452A1 (es) Modificacion a cristal de una sustancia activa de medicamen- to
KR890009400A (ko) 다이클로닌 Hcl및 페놀을 함유하는 약제학적 조성물
HUP0302970A2 (hu) Aminosavak felhasználása fájdalom kezelésére, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
BR9908199A (pt) Derivados de sulfonamida
BR0001144B1 (pt) Composicão farmacêutica de diclofenaco à base de vitamina-e, papaína e hialuronidase
BR0207867A (pt) Sal de benzoilguanidina